PT IKAPHARMINDO PUTRAMAS Tbk
Pharmaceutical Laboratories

("Perseroan")

PENGUMUMAN
RINGKASAN RISALAH RAPAT UMUM PEMEGANG SAHAM LUAR BIASA

Direksi Perseroan dengan ini mengumumkan kepada para Pemegang Saham Perseroan bahwa Perseroan telah mengadakan Rapat Umum Pemegang Saham Luar Biasa ("**RUPSLB**").

Dalam rangka memenuhi Peraturan Otoritas Jasa Keuangan No.15/POJK.04/2020 tentang Rencana dan Penyelenggaraan Rapat Umum Pemegang Saham Perusahaan Terbuka, Perseroan menyampaikan Ringkasan Risalah RUPSLB sebagai berikut:

RUPSLB dilaksanakan pada :
Hari & Tanggal : **Kamis, 24 April 2025**
Jam : 10.31 – 10.37 WIB
Tempat : Hotel Santika Kelapa Gading - Jakarta
Mahaka Square, Jalan Kelapa Nias Raya Blok HF 3 Kelapa Gading
Jakarta Utara 14240 - Indonesia

Mata Acara :
Persetujuan pembebanan atas aset-aset tertentu milik Perseroan kepada Bank yang diberikan berdasarkan dokumen-dokumen jaminan yang akan ditandatangani oleh Perseroan sehubungan dengan perolehan dan penerimaan Fasilitas berdasarkan Perjanjian Pinjaman dan/atau transaksi-transaksi FX dan persetujuan penandatanganan oleh Direksi atas dokumen-dokumen jaminan (termasuk tiap perubahan, modifikasi, novasi, atau tambahan terhadap dokumen-dokumen jaminan tersebut) dan dokumen lain dan/atau instrument lain yang berhubungan dengan perolehan dan penerimaan Fasilitas oleh Perseroan sesuai dengan ketentuan Pasal 102 (1) b Undang-undang Nomor 40 Tahun 2007 tentang Perseroan Terbatas.

(Untuk selanjutnya disebut "**Rapat**")

Untuk kepentingan Perseroan dibuat Berita Acara Rapat Umum Pemegang Saham Luar Biasa Perseroan, tertanggal 24 April 2025, dengan nomor 118.

Kehadiran Anggota Direksi Dan Dewan Komisaris Perseroan:
Anggota Direksi yang hadir dalam Rapat :
Direktur Utama : Tuan KARTONO;
Direktur : Tuan AYI SAEPUDIN;
Direktur : Nyonya ELIZA ARLENA WINATA;
Anggota Dewan Komisaris yang hadir dalam Rapat :
Komisaris Independen : Tuan SUSANTO LAM.

Pimpinan Rapat:
-Rapat dipimpin oleh Tuan SUSANTO LAM, selaku Komisaris Independen Perseroan.

Kehadiran Pemegang Saham :
-Rapat telah dihadiri oleh para pemegang saham dan kuasa pemegang saham yang mewakili 1.527.284.200 saham atau mewakili 90,66% dari 1.684.662.500 saham yang merupakan seluruh saham dengan hak suara yang sah yang telah dikeluarkan oleh Perseroan setelah dikurangi dengan jumlah saham yang telah dibeli kembali oleh Perseroan.

Pengajuan Pertanyaan dan/atau Pendapat :
-Pemegang saham dan kuasa pemegang saham diberi kesempatan untuk mengajukan pertanyaan dan/atau pendapat untuk mata acara Rapat, namun tidak ada pemegang saham dan kuasa pemegang saham yang mengajukan pertanyaan dan/atau pendapat;

Mekanisme Pengambilan Keputusan :
-Pengambilan keputusan mata acara Rapat dilakukan berdasarkan musyawarah untuk mufakat, dalam hal musyawarah untuk mufakat tidak tercapai, pengambilan keputusan dilakukan dengan pemungutan suara.

Hasil Pemungutan Suara :
-Jumlah suara blanko/abstain : 208.068.800 suara.
-Jumlah suara tidak setuju : - suara.
-Jumlah suara setuju : 1.319.215.400 suara.
-Sehingga total suara setuju : 1.527.284.200 suara, atau sebesar 100%, atau lebih dari 3/4 bagian dari jumlah seluruh suara yang dikeluarkan secara sah dalam Rapat.

Jumlah suara blanko/abstain	Jumlah suara tidak setuju	Jumlah suara setuju	Total suara setuju	(%)
208.068.800	-	1.319.215.400	1.527.284.200	100

Keputusan Rapat :
Menyetujui pembebanan atas aset-aset tertentu milik Perseroan kepada Bank yang diberikan berdasarkan dokumen-dokumen jaminan yang akan ditandatangani oleh Perseroan sehubungan dengan perolehan dan penerimaan Fasilitas berdasarkan Perjanjian Pinjaman dan/atau transaksi-transaksi FX dan menyetujui penandatanganan oleh Direksi atas dokumen-dokumen jaminan (termasuk tiap perubahan, modifikasi, novasi, atau tambahan terhadap dokumen-dokumen jaminan tersebut) dan dokumen lain dan/atau instrument lain yang berhubungan dengan perolehan dan penerimaan Fasilitas oleh Perseroan sesuai dengan ketentuan Pasal 102 (1) b Undang-undang Nomor 40 Tahun 2007 tentang Perseroan Terbatas.

Jakarta, 24 April 2025
Direksi
PT Ikapharmindo Putramas Tbk

PT IKAPHARMINDO PUTRAMAS Tbk
Pharmaceutical Laboratories

("Company")

ANNOUNCEMENT

SUMMARY OF MINUTES OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

The Board of Directors of the Company hereby announces to the Shareholders of the Company that the Company has held an Annual General Meeting of Shareholders ("**AGMS**").

In order to make compliance towards Financial Services Authority Regulation No.15/POJK.04/2020 concerning Planning and Implementation of the General Meeting of Shareholders of Public Listed Companies, the Company submitted Summary of Minutes of AGMS as follows:

AGMS is held on:

Day & Date : **Thursday, April 24, 2025**
Time : 09.21 – 10.12 Western Indonesia Time
Venue : Hotel Santika Kelapa Gading - Jakarta
Mahaka Square, Jalan Kelapa Nias Raya Blok HF 3 Kelapa Gading
Jakarta Utara 14240 – Indonesia

Agenda :

1. Approval and validation of the Company's Annual Report for the 2024 financial year, including the Company's Activity Report, the Board of Commissioners' Supervisory Report and the Company's Financial Report for the 2024 financial year as well as granting full release and discharge (acquit et decharge) to the Company's Board of Directors and Board of Commissioners for the management and supervision actions they conducted in the 2024 financial year.
2. Affirmation for the use of the Company's Net Profit Balance for the 2024 financial year.
3. Report and realization on accountability for the Fund which obtained from Company's Public Offering.
4. Appointment of a Public Accountant and/or Public Accounting Firm to audit the Company's Financial Statements for the financial year which ends in December 31, 2025, and to grant authority to determine the honorarium of the Public Accountant and/or Public Accounting Firm along with other requirements.
5. Stipulation of honorarium, salary and other allowances for members of the Company's Board of Commissioners and Board of Directors.

(Hereinafter referred to as "**Meeting**").

On behalf of the Company, a Deed of Minutes of the Company's Extraordinary General Meeting of Shareholders is made, dated April 24, 2025, with Number 118.

The attendance of Members of the Board of Directors and Board of Commissioners of the Company:

Members of the Board of Directors who attended the Meeting:

President Director : Mr. KARTONO;

Director : Mr. AYI SAEPUDIN;

Director : Mrs. Eliza Arlena Winata;

Members of the Board of Commissioners who attended the Meeting:

Independent Commissioner : Mr. SUSANTO LAM.

Meeting Chairman:

-The meeting was chaired by Mr. SUSANTO LAM, as the Company's Independent Commissioner.

The Attendance of Shareholders:

-The Meeting has been attended by shareholders and shareholders' proxies representing 1.527.283.600 shares or represented 90,66% of 1.684.662.500 shares which are all shares with valid voting rights which issued by the Company after deducting the number of shares that have been repurchased by the Company.

Submission of Questions and/or Opinions:

-Shareholders and shareholders' proxies are given the opportunity to ask questions and/or gave opinions for agenda of the Meeting, but none of the shareholders and shareholders' proxies ask questions and/or gave opinions;

Decision Making Mechanism:

-Decision making of agenda is carried out based on deliberation for consensus, in theevent that deliberation for consensus is not reached, decision making is carried out by voting.

Voting Results:
First Meeting Agenda:
-Number of blank votes/abstain : 208.068.800 votes
-Number of dissenting votes : - votes.
-Number of affirmative votes : 1.319.214.800 votes.
-So that the total votes are affirmative : 1.527.283.600 votes, or by 100%, or more than 1/2 of the total number of votes legally cast at the Meeting.

Number of blank votes/abstain	Number of dissenting votes	Number of affirmative votes	Total affirmative votes	(%)
208.068.800	-	1.319.214.800	1.527.283.600	100

Second Meeting Agenda:
-Number of blank votes/abstain : 208.068.800 votes
-Number of dissenting votes : - votes.
-Number of affirmative votes : 1.319.214.800 votes.
-So that the total votes are affirmative : 1.527.283.600 votes, or by 100%, or more than 1/2 of the total number of votes legally cast at the Meeting.

Number of blank votes/abstain	Number of dissenting votes	Number of affirmative votes	Total affirmative votes	(%)
208.068.800	-	1.319.214.800	1.527.283.600	100

Third Meeting Agenda:
-Number of blank votes/abstain : 208.068.800 votes
-Number of dissenting votes : - votes.
-Number of affirmative votes : 1.319.214.800 votes.
-So that the total votes are affirmative : 1.527.283.600 votes, or by 100%, or more than 1/2 of the total number of votes legally cast at the Meeting.

Number of blank votes/abstain	Number of dissenting votes	Number of affirmative votes	Total affirmative votes	(%)
208.068.800	-	1.319.214.800	1.527.283.600	100

Fourth Meeting Agenda:
-Number of blank votes/abstain : 208.068.800 votes
-Number of dissenting votes : - votes.
-Number of affirmative votes : 1.319.214.800 votes.
-So that the total votes are affirmative : 1.527.283.600 votes, or by 100%, or more than 1/2 of the total number of votes legally cast at the Meeting.

Number of blank votes/abstain	Number of dissenting votes	Number of affirmative votes	Total affirmative votes	(%)
208.068.800	-	1.319.214.800	1.527.283.600	100

Fifth Meeting Agenda:
-Number of blank votes/abstain : 208.068.800 votes
-Number of dissenting votes : - votes.
-Number of affirmative votes : 1.319.214.800 votes.
-So that the total votes are affirmative : 1.527.283.600 votes, or by 100%, or more than 1/2 of the total number of votes legally cast at the Meeting.

Number of blank votes/abstain	Number of dissenting votes	Number of affirmative votes	Total affirmative votes	(%)
208.068.800	-	1.319.214.800	1.527.283.600	100

Meeting Decision:
First Meeting Agenda Decision:

- To approve and validate on the Company's Annual Report for the 2024 financial year, including the Company's Activity Report, the Board of Commissioners' Supervisory Report and the Company's Financial Report for the 2024 financial year as well as granting full release and discharge (acquit et decharge) to the Company's Board of Directors and Board of Commissioners for the management and supervision actions they conducted in the 2024 financial year.

Second Meeting Agenda Decision:

a. To affirm the use of Company's Net Profit Balance for the 2024 financial year in amount of Rp5,014,949,522 (Five billion fourteen million nine hundred forty nine thousand five hundred twenty two Rupiah), as follows:

   i. Not to distribute cash dividends to the Company's shareholders;
   ii. Rp2,000,000,000 (two billion Rupiah), is reserved and recorded as a reserve fund;
   iii. the remainder is recorded as retained earnings, to increase the Company's working capital;

b. To grant power and authority to the Company's Board of Directors to take every and all necessary actions in connection with the above decision, in accordance with applicable laws and regulations.

Third Meeting Agenda Decision:

- To accept report and realization on accountability for the Fund which obtained from Company's Public Offering.

Fourth Meeting Agenda Decision:

- To grant authority and power to the Company's Board of Commissioners to appoint a Public Accountant and/or Public Accounting Firm, with independent and registered with the Financial Services Authority criterias, who will audit Company's financial statements for the 2025 financial year which currently being considered and evaluated for the further appointment of a Public Accountant and/or Public Accounting Firm, by making into consideration the recommendation from Audit Committee, and to determine the honorarium of the Public Accountant and the terms of appointment including dismissal or appointment of a replacement.

Fifth Meeting Agenda Decision:

a. To determine the honorarium, salary, and other allowances for the Company's Board of Commissioners as a whole for the 2025 financial year, in the same amount as the amount of salary and other allowances provided in the 2024 financial year, or if there is an increase, the amount of the increase does not exceed 6% (six percent) of the amount of salary and other allowances provided in the 2024 financial year, and authorize the Board of Commissioners Meeting to determine its allocation, by considering the recommendation from Nomination and Remuneration Committee.

b. To grant authority to Company's Board of Commissioners to determine remuneration in the form of salary and other allowances for the Company's Board of Directors, by considering the recommendation from Nomination and Remuneration Committee.

Jakarta, April 24, 2025
Board of Directors

PT Ikapharmindo Putramas Tbk